Agreement

Maxcor Lifesience Forges Agreement with Micell for Drug Coating Technology

Opto Circuits (I) Ltd's (OCI) newly incorporated subsidiary Maxcor Lifesience, Inc, entered into a strategic cooperation agreement with Micell Technologies, Inc, based in Raleigh, North Carolina, USA.

Maxcor and Micell will co-operate in developing and commercialising leading edge Rapamycin (Sirolimus) - based Drug Eluting Stents (DES) and Drug Eluting Balloons (DEB) which will complement OCI's present range of successful paclitaxel-based drug-device combination products.

Offering products with both compounds will enable OCI to maximise its market by way of addressing additional clinical scenarios. The jointly-developed offerings will have cardio-vascular applications that will advance the treatment of many clinical conditions while also minimizing their potential risks or side-effects.

Said Vinod Ramnani, Chairman & Managing Director, OCI, "The science of medicating an interventional device is highly complex and requires exceptional clinical expertise and know-how. We are proud to begin working with Micell which has a strong intellectual property portfolio in this arena and which we hope will help give momentum to our jointly developed new products in new and regulated markets."

OCI is a 100 per cent EOU and a leading manufacturer of healthcare equipment in India. The product profile includes digital thermometers, sensors, probes, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits for medical device and drug delivery applications. Its first product, MiStent, is a rapid absorbing coated drug-eluting stent (DES) with precise control of drug release and pharmacokinetics.

EH News Bureau